Compare Cipla with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs IPCA LABS - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA IPCA LABS CIPLA/
IPCA LABS
 
P/E (TTM) x 33.1 23.7 139.3% View Chart
P/BV x 4.7 8.5 55.0% View Chart
Dividend Yield % 0.4 0.1 306.5%  

Financials

 CIPLA   IPCA LABS
EQUITY SHARE DATA
    CIPLA
Mar-20
IPCA LABS
Mar-19
CIPLA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs5861,042 56.2%   
Low Rs357590 60.5%   
Sales per share (Unadj.) Rs207.0298.6 69.3%  
Earnings per share (Unadj.) Rs18.635.0 53.1%  
Cash flow per share (Unadj.) Rs33.249.4 67.1%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.80.4 230.9%  
Book value per share (Unadj.) Rs195.5247.1 79.1%  
Shares outstanding (eoy) m806.35126.35 638.2%   
Bonus/Rights/Conversions ESOSESOS-  
Price / Sales ratio x2.32.7 83.3%   
Avg P/E ratio x25.323.3 108.7%  
P/CF ratio (eoy) x14.216.5 86.1%  
Price / Book Value ratio x2.43.3 73.0%  
Dividend payout %21.58.6 250.9%   
Avg Mkt Cap Rs m379,912103,108 368.5%   
No. of employees `00025.813.4 192.3%   
Total wages/salary Rs m30,2707,874 384.4%   
Avg. sales/employee Rs Th6,459.62,807.0 230.1%   
Avg. wages/employee Rs Th1,171.2585.8 199.9%   
Avg. net profit/employee Rs Th580.2329.0 176.4%   
INCOME DATA
Net Sales Rs m166,94937,732 442.5%  
Other income Rs m3,442577 596.7%   
Total revenues Rs m170,39138,309 444.8%   
Gross profit Rs m32,0606,901 464.6%  
Depreciation Rs m11,7471,824 643.9%   
Interest Rs m1,974189 1,045.9%   
Profit before tax Rs m21,7825,465 398.6%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3121,042 605.5%   
Profit after tax Rs m14,9954,422 339.1%  
Gross profit margin %19.218.3 105.0%  
Effective tax rate %29.019.1 151.9%   
Net profit margin %9.011.7 76.6%  
BALANCE SHEET DATA
Current assets Rs m117,03823,778 492.2%   
Current liabilities Rs m43,93110,975 400.3%   
Net working cap to sales %43.833.9 129.1%  
Current ratio x2.72.2 123.0%  
Inventory Days Days96104 92.2%  
Debtors Days Days8566 129.0%  
Net fixed assets Rs m107,42420,368 527.4%   
Share capital Rs m1,613253 638.1%   
"Free" reserves Rs m156,01830,971 503.8%   
Net worth Rs m157,63031,224 504.8%   
Long term debt Rs m23,6931,409 1,682.1%   
Total assets Rs m236,62645,507 520.0%  
Interest coverage x12.030.0 40.2%   
Debt to equity ratio x0.20 333.2%  
Sales to assets ratio x0.70.8 85.1%   
Return on assets %7.210.1 70.8%  
Return on equity %9.514.2 67.2%  
Return on capital %12.817.3 74.1%  
Exports to sales %33.045.9 72.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs m55,17517,308 318.8%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m56,03617,308 323.8%   
Fx outflow Rs m6,7646,266 107.9%   
Net fx Rs m49,27211,042 446.2%   
CASH FLOW
From Operations Rs m30,6854,923 623.3%  
From Investments Rs m1,040-1,563 -66.6%  
From Financial Activity Rs m-29,488-1,832 1,609.6%  
Net Cashflow Rs m2,3401,528 153.2%  

Share Holding

Indian Promoters % 16.0 45.9 34.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.4 107.0%  
FIIs % 23.7 25.3 93.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.4 150.6%  
Shareholders   161,166 36,892 436.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA  ORCHID PHARMA  GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Apr 15, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS